The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The global allergy conjunctivitis market is projected to increase from $2.12 billion in 2022 to $2.27 billion in 2023, with a 5.6% CAGR. By 2027, it is expected to reach $2.93 billion, growing at a 5.1% CAGR.

North America was the largest region in the allergy conjunctivitis market share in 2022.

Allergy Conjunctivitis Market Driver
Increasing exposure to air pollutants and chemicals propels allergy conjunctivitis market growth. Human eyes, highly sensitive, face continuous risk from airborne toxins. Prolonged exposure causes various eye problems, necessitating treatment, including allergic conjunctivitis, allergies, burning, watering, blurred vision, redness, itching, and discomfort. In 2021, the United States Environmental Protection Agency (EPA) reported about 67 million tons of pollutants released into the atmosphere. Thus, rising exposure to air pollutants and chemicals drives allergy conjunctivitis market growth.

View More On The Allergy Conjunctivitis Market Report 2023 – https://www.thebusinessresearchcompany.com/report/allergy-conjunctivitis-global-market-report

Prominent Allergy Conjunctivitis Market Trend
Product innovation gains traction in the allergy conjunctivitis market. Leading companies prioritize innovative product development for market reinforcement. For example, in February 2020, US-based medical company Alcon introduced Pataday, a non-prescription daily allergy itch relief eye drop. Pataday is the first of its kind, containing the top doctor-recommended allergy itch relief ingredient. It will be available nationwide in major retail and online stores, backed by a multimillion-dollar media campaign targeting eye allergy sufferers.

Allergy Conjunctivitis Market Prominent Players
Major players in the allergy conjunctivitis market are Allergan plc., Santen Pharmaceutical Co Ltd., Bausch & Lomb Incorporated, Novartis AG, Sun Pharmaceutical Industries Ltd., Ocular Therapeutix Inc., Alcon, Eton Pharmaceutical, AbbVie Inc., Ajanta Pharma Limited, Akron Operating Company LLC, Alembic Pharmaceuticals Ltd., Cipla Ltd., Grevis Pharmaceutical Private Limited, Indoco RemediesLtd., Jabs Biotech Pvt. Ltd., JAWA Pharmaceuticals Pvt. Ltd., Auven Therapeutics, and Atopix Therapeutics Ltd.

Request A Sample Of The Global Allergy Conjunctivitis Market Report 2023:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8806&type=smp

Key Allergy Conjunctivitis Market Segments
The global allergy conjunctivitis market is segmented –
1) By Drug Class: Antihistamines and Mast Cell Stabilizers, Corticosteroids, Other Drug Classes
2) By Disease Type: Mild, Severe
3) By Distribution Channel: Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Pharmacies

The Allergy Conjunctivitis Global Market Report 2023  provides a comprehensive overview on the allergy conjunctivitis market size, trends and drivers, opportunities, strategies, and companies analysis. The countries covered in the allergy conjunctivitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

View More Related Reports –
Allergy Diagnostics Global Market Report 2023
Allergy Immunotherapy Global Market Report 2023
Conjunctivitis Treatment Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model